Financials ALK-Abelló A/S

Equities

ALK B

DK0061802139

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 15:59:44 03/05/2024 BST 5-day change 1st Jan Change
148.8 DKK +13.59% Intraday chart for ALK-Abelló A/S +14.46% +47.04%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 17,801 27,291 37,650 21,222 22,384 32,913 - -
Enterprise Value (EV) 1 18,475 27,697 37,922 21,430 22,374 32,548 31,797 30,611
P/E ratio -356 x 1,101 x 173 x 63.6 x 46 x 42.1 x 30.2 x 24.7 x
Yield - - - - - - - -
Capitalization / Revenue 5.44 x 7.82 x 9.61 x 4.7 x 4.64 x 6.11 x 5.49 x 4.92 x
EV / Revenue 5.64 x 7.93 x 9.68 x 4.75 x 4.64 x 6.04 x 5.31 x 4.57 x
EV / EBITDA 76.7 x 70.1 x 71 x 30.3 x 24.6 x 25.4 x 18.4 x 14.9 x
EV / FCF -739 x 495 x 188 x 330 x 76.6 x 102 x 37.9 x 26.9 x
FCF Yield -0.14% 0.2% 0.53% 0.3% 1.31% 0.98% 2.64% 3.72%
Price to Book 5.74 x 8.83 x 11 x 5.34 x 5.06 x 6.32 x 5.22 x 4.31 x
Nbr of stocks (in thousands) 217,745 218,327 219,534 220,946 221,189 221,189 - -
Reference price 2 81.75 125.0 171.5 96.05 101.2 148.8 148.8 148.8
Announcement Date 05/02/20 10/02/21 08/02/22 03/02/23 08/02/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 3,274 3,491 3,916 4,511 4,824 5,389 5,992 6,695
EBITDA 1 241 395 534 708 911 1,280 1,732 2,049
EBIT 1 -14 150 292 470 666 1,009 1,440 1,730
Operating Margin -0.43% 4.3% 7.46% 10.42% 13.81% 18.72% 24.04% 25.85%
Earnings before Tax (EBT) 1 -31 101 279 447 647 1,008 1,429 1,730
Net income 1 -50 25 219 335 486 779.7 1,096 1,340
Net margin -1.53% 0.72% 5.59% 7.43% 10.07% 14.47% 18.29% 20.02%
EPS 2 -0.2295 0.1135 0.9900 1.510 2.200 3.535 4.926 6.036
Free Cash Flow 1 -25 56 202 65 292 320.5 838.7 1,139
FCF margin -0.76% 1.6% 5.16% 1.44% 6.05% 5.95% 14% 17.01%
FCF Conversion (EBITDA) - 14.18% 37.83% 9.18% 32.05% 25.04% 48.41% 55.58%
FCF Conversion (Net income) - 224% 92.24% 19.4% 60.08% 41.11% 76.51% 84.95%
Dividend per Share 2 - - - - - - - -
Announcement Date 05/02/20 10/02/21 08/02/22 03/02/23 08/02/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 1,099 1,155 1,045 1,062 1,249 1,234 1,135 1,110 1,345 1,351 1,246 1,237 1,516
EBITDA 1 136 272 107 128 201 288 157 208 258 - 235 289 405.5
EBIT 1 79 215 49 68 138 228 97 147 194 316 163.5 218.5 335
Operating Margin 7.19% 18.61% 4.69% 6.4% 11.05% 18.48% 8.55% 13.24% 14.42% 23.39% 13.12% 17.66% 22.09%
Earnings before Tax (EBT) 1 74 217 56 70 104 217 89 155 186 - 147 206 317
Net income 1 76 163 42 52 78 163 66 117 140 - 120 160.9 249.5
Net margin 6.92% 14.11% 4.02% 4.9% 6.24% 13.21% 5.81% 10.54% 10.41% - 9.63% 13.01% 16.45%
EPS 2 0.3450 0.7400 0.1900 0.2300 0.3500 0.7000 0.3000 0.5000 0.7000 - 0.5350 0.7200 1.130
Dividend per Share - - - - - - - - - - - - -
Announcement Date 08/02/22 12/05/22 11/08/22 10/11/22 03/02/23 09/05/23 24/08/23 15/11/23 08/02/24 02/05/24 - - -
1DKK in Million2DKK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 674 406 272 208 - - - -
Net Cash position 1 - - - - 10 365 1,116 2,302
Leverage (Debt/EBITDA) 2.797 x 1.028 x 0.5094 x 0.2938 x - - - -
Free Cash Flow 1 -25 56 202 65 292 321 839 1,139
ROE (net income / shareholders' equity) -1.6% 0.8% 6.6% 9% 11.5% 16.1% 19.4% 19.5%
ROA (Net income/ Total Assets) -0.97% 0.45% 3.84% 5.52% 7.46% 11% 14.8% 15.1%
Assets 1 5,181 5,529 5,696 6,069 6,517 7,090 7,400 8,868
Book Value Per Share 2 14.30 14.20 15.60 18.00 20.00 23.50 28.50 34.50
Cash Flow per Share 2 0.6100 1.380 2.140 1.900 3.000 3.500 5.500 6.100
Capex 1 147 196 263 353 379 325 382 410
Capex / Sales 4.49% 5.61% 6.72% 7.83% 7.86% 6.03% 6.38% 6.12%
Announcement Date 05/02/20 10/02/21 08/02/22 03/02/23 08/02/24 - - -
1DKK in Million2DKK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
148.8 DKK
Average target price
143.2 DKK
Spread / Average Target
-3.76%
Consensus
  1. Stock Market
  2. Equities
  3. ALK B Stock
  4. Financials ALK-Abelló A/S